KODK

Eastman Kodak Company: Q2 2007 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007. Eastman Kodak Company (Kodak) is a large accelerated filer engaged in imaging and related technologies. The reporting period is significantly impacted by the divestiture of the Health Group segment, which was sold on April 30, 2007, and is now reported as discontinued operations. The company operates three primary reportable segments: Consumer Digital Imaging Group (CDG), Film Products Group (FPG), and Graphic Communications Group (GCG).

Key Financial Metrics

Material Changes vs. Prior Period

• Discontinued Operations: The primary driver of profitability was the sale of the Health Group segment, generating a pre-tax gain of $980 million and net earnings of $727 million in Q2 2007. Without this, the company reported a net loss from continuing operations.
• Continuing Operations Performance: Net sales from continuing operations declined 7% year-over-year in Q2 due to volume declines in consumer film and snapshot printing, partially offset by favorable foreign exchange. However, the loss from continuing operations improved significantly (from $355M loss to $152M loss) due to aggressive cost reductions.
• Restructuring Costs: Restructuring charges increased to $295 million in Q2 2007 (up from $156 million in Q2 2006). This included a $238 million non-cash impairment charge related to the sale of the Xiamen, China manufacturing facility.
• Debt Reduction: Long-term debt decreased by approximately $1.38 billion year-over-year. The company used proceeds from the Health Group sale to fully repay its $1.15 billion Secured Term Debt in May 2007.
• Segment Results:
  • CDG: Sales down 10%; loss improved to $64 million from $133 million.
  • FPG: Sales down 15%; earnings improved to $133 million from $119 million.
  • GCG: Sales up 2%; earnings improved to $37 million from $16 million.

Guidance, Outlook, and Risks

• Restructuring Program: The 2004-2007 Restructuring Program has been expanded. The company now expects total employment reductions of 28,000 to 30,000 positions and total charges of $3.6 billion to $3.8 billion. The program is expected to generate annual cost savings of approximately $1.6 billion to $1.8 billion.
• Liquidity: Cash and cash equivalents increased to $1.925 billion. The company maintains $1.087 billion in committed bank lines of credit. Management believes cash flow and asset sales will be sufficient to cover working capital, debt reduction, and restructuring payments.
• Dividends: A semi-annual cash dividend of $0.25 per share was declared and paid in July 2007.
• Contingencies:
  • Environmental: Accrued liabilities for environmental remediation total $146 million, primarily related to the Kodak Park site in Rochester, NY.
  • Legal: The SEC is conducting an informal inquiry regarding the 2003-2004 financial statement restatement.
  • Convertible Securities: $575 million in convertible notes are outstanding. At current credit ratings (B2/B), holders have the option to convert these notes to common stock.

Investor Verification Checklist

• Continuing Operations Viability: Verify the sustainability of earnings excluding the one-time gain from the Health Group sale, as continuing operations remain loss-making.
• Restructuring Execution: Monitor the progress of the expanded 2004-2007 restructuring program and the realization of the projected $1.6 billion+ in annual cost savings.
• Debt Covenants: Confirm continued compliance with the Secured Credit Agreement covenants (Debt/EBITDA and EBITDA/Interest ratios) following the debt payoff.
• Legacy Business Decline: Assess the pace of volume declines in the Film Products Group (FPG) and Retail Printing within CDG, which are key drivers of revenue contraction.
• Environmental Liabilities: Review updates on the Kodak Park remediation costs, as estimates can vary significantly over time.